366 results
8-K
EX-99.1
EXEL
Exelixis Inc
30 Apr 24
Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update
4:12pm
. We believe the recent restructuring of our business, announced in January, further enhances our integrated research, development and commercial … , partially offset by a decrease in development cost reimbursements earned.
Research and development expenses for the quarter ended March 31, 2024
8-K
EX-99.1
EXEL
Exelixis Inc
6 Feb 24
Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update
4:28pm
on the research, development, commercial and financial fronts,” said Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis. “This year, we … on the cabozantinib experience and the integrated research, development and commercial capabilities highlighted at our recent R&D Day, we are working
8-K
EX-99.1
q3nbwmpft2htkha
8 Jan 24
Results of Operations and Financial Condition
9:06am
8-K
EX-99.1
aimwq4xu
1 Nov 23
Exelixis Announces Third Quarter 2023 Financial Results and Provides Corporate Update
4:08pm
8-K
EX-99.1
zuwmkhts xmwqgt
1 Aug 23
Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update
4:11pm
DEFA14A
mk9286 caj
16 May 23
Additional proxy soliciting materials
6:33pm
DEFA14A
jjpubuyt
15 May 23
Additional proxy soliciting materials
8:05am
8-K
EX-99.1
4acflpfi3ayy 3hq
9 May 23
Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update
4:13pm
DEFC14A
eeyi2d65
3 May 23
Proxy in contested solicitation
10:28am
DEFA14A
EX-1
3hn znes1
1 May 23
Additional proxy soliciting materials
8:55pm
DEFA14A
9aklu
1 May 23
Additional proxy soliciting materials
5:12pm
DEFC14A
eb4obob
1 May 23
Proxy in contested solicitation
4:58pm
PRRN14A
u08uinqz
21 Apr 23
Revised preliminary proxy statement filed by non-management
5:04pm